A Phase 1, Single- Center, Randomized, Double-blind, Vehicle And Active Comparator-controlled Trial To Evaluate The Antipsoriatic Activity And Safety Of A Topically Applied Pf-06263276 Formulation In A Psoriasis Plaque Test
Phase of Trial: Phase I
Latest Information Update: 11 Jun 2016
Price : $35 *
At a glance
- Drugs PF 6263276 (Primary) ; Calcipotriol; Calcipotriol; Tofacitinib
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Pfizer
- 31 Aug 2018 Biomarkers information updated
- 05 Mar 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 10 Dec 2014 Planned End Date changed from 1 Oct 2014 to 1 Feb 2015 as reported by ClinicalTrials.gov.